SEC Form 144 filed by Veracyte Inc.

$VCYT
Medical Specialities
Health Care
Get the next $VCYT alert in real time by email

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Get the next $VCYT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VCYT

DatePrice TargetRatingAnalyst
3/20/2025$45.00Buy
Craig Hallum
12/5/2024$38.00 → $37.00Buy → Neutral
Goldman
11/15/2024$50.00Outperform
Wolfe Research
10/16/2024$43.00Buy
UBS
10/10/2024$40.00Buy
Guggenheim
2/23/2024$30.00 → $33.00Buy
Needham
1/18/2023Outperform → Mkt Perform
Raymond James
1/5/2023$33.00Sector Outperform
Scotiabank
More analyst ratings

$VCYT
Press Releases

Fastest customizable press release news feed in the world

See more
  • New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

    Findings from TOMBOLA Trial Were Presented at EAU25 Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based blood testing and earlier compared to standard imaging. The findings, from the large, independent, multicenter, interventional TOMBOLA trial (NCT04138628), were shared in an oral presentation at the 40th Annual European Association of Urology Congress (EAU25) in Madrid by Iver Nordentoft, Ph.D., Aarhus University (Abstract A0162: "C

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company's minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter trial. The EAU25 meeting is taking place March 21-24 at IFEMA Madrid in Spain. "These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

    Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact

    $VCYT
    Medical Specialities
    Health Care

$VCYT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VCYT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VCYT
SEC Filings

See more

$VCYT
Leadership Updates

Live Leadership Updates

See more
  • Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

    Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo

    $VCYT
    Medical Specialities
    Health Care

$VCYT
Financials

Live finance-specific insights

See more
  • Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

    Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/8em9yd38. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://invest

    $VCYT
    Medical Specialities
    Health Care
  • Veracyte Announces Third Quarter 2024 Financial Results

    Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation," said Marc Stapley, Veracyte's chief executive officer. "Looking ahead, we see tremendous opportunities for further market penetration for both Decipher and Afirma, to serve even more patients and their physicians. We also remain excited about our focused p

    $VCYT
    Medical Specialities
    Health Care

$VCYT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more